Adalimumab-adaz Injection shortage
To Be DiscontinuedAdalimumab-adaz Injection is currently listed as To Be Discontinued in the FDA Drug Shortage Database. Reported reason: Not specified.
Therapeutic category
Dosage form
Injection
Routes
SUBCUTANEOUS
Last updated
01/13/2026
Strength variants
- Not specified
Need sourcing help for Adalimumab-adaz Injection?
Get connected with licensed distributors and 503B compounders that can fulfill orders during active shortages. Verified suppliers, no spam.
Connect with a sourcing partnerManufacturers reporting shortage
- Sandoz Inc.800-525-8747To Be Discontinued
- Sandoz Inc.800-525-8747To Be Discontinued
- Sandoz Inc.800-525-8747To Be Discontinued
- Sandoz Inc.800-525-8747To Be Discontinued
- Sandoz Inc.800-525-8747To Be Discontinued
- Sandoz Inc.800-525-8747To Be Discontinued
- Sandoz Inc.800-525-8747To Be Discontinued
- Sandoz Inc.800-525-8747To Be Discontinued
Reason for shortage
ad slot 300x250
Related shortages in Rheumatology
Methylprednisolone Acetate Injection
- Category
- Rheumatology
- Reason
- Demand increase for the drug
- Updated
- 04/08/2026
Methylprednisolone Acetate Injection
- Category
- Rheumatology
- Reason
- Demand increase for the drug
- Updated
- 04/08/2026
Methylprednisolone Acetate Injection
- Category
- Rheumatology
- Reason
- Demand increase for the drug
- Updated
- 04/07/2026
Methylprednisolone Acetate Injection
- Category
- Rheumatology
- Reason
- Not specified
- Updated
- 04/06/2026
Methylprednisolone Acetate Injection
- Category
- Rheumatology
- Reason
- Not specified
- Updated
- 04/06/2026
Methylprednisolone Acetate Injection
- Category
- Rheumatology
- Reason
- Shortage of an active ingredient
- Updated
- 04/06/2026
This information is not medical advice. Consult your pharmacist. Data is sourced from the FDA Drug Shortage Database and may not reflect real-time inventory at your facility. ShortageWatch is independent and not affiliated with the FDA.